211 related articles for article (PubMed ID: 37802603)
1. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8
Yu A; Hu J; Fu L; Huang G; Deng D; Zhang M; Wang Y; Shu G; Jing L; Li H; Chen X; Yang T; Wei J; Chen Z; Zu X; Luo J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802603
[TBL] [Abstract][Full Text] [Related]
2. S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8
Li H; Chen J; Li Z; Chen M; Ou Z; Mo M; Wang R; Tong S; Liu P; Cai Z; Zhang C; Liu Z; Deng D; Liu J; Cheng C; Hu J; Zu X
Adv Sci (Weinh); 2023 Sep; 10(25):e2300110. PubMed ID: 37414584
[TBL] [Abstract][Full Text] [Related]
3. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
[TBL] [Abstract][Full Text] [Related]
4. BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.
Cai Z; Chen J; Yu Z; Li H; Liu Z; Deng D; Liu J; Chen C; Zhang C; Ou Z; Chen M; Hu J; Zu X
Adv Sci (Weinh); 2023 Mar; 10(8):e2207155. PubMed ID: 36642843
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
6. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
7. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
[TBL] [Abstract][Full Text] [Related]
8. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
9. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8
Wu Q; Liu Z; Gao Z; Luo Y; Li F; Yang C; Wang T; Meng X; Chen H; Li J; Kong Y; Dong C; Sun S; Chen C
Theranostics; 2023; 13(4):1381-1400. PubMed ID: 36923542
[No Abstract] [Full Text] [Related]
10. PD1
Wu C; Duan L; Li H; Liu X; Cai T; Yang Y; Yin Y; Chang W; Zhong L; Zhang L; Cheng Y; Qin H; Wen Z; Wang H; Mai S
Clin Transl Med; 2023 Jun; 13(6):e1303. PubMed ID: 37313656
[TBL] [Abstract][Full Text] [Related]
11. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8
Xia W; Zhang S; Duan H; Wang C; Qian S; Shen H
Med Oncol; 2022 Jan; 39(3):37. PubMed ID: 35059863
[TBL] [Abstract][Full Text] [Related]
12. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
13. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
15. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
Lin H; Fu L; Zhou X; Yu A; Chen Y; Liao W; Shu G; Zhang L; Tan L; Liang H; Wang Z; Deng Q; Wang J; Jin M; Chen Z; Wei J; Cao J; Chen W; Li X; Li P; Lu J; Luo J
Cancer Lett; 2024 Jul; 593():216807. PubMed ID: 38462037
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
[TBL] [Abstract][Full Text] [Related]
17. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
18. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of CD8
Mortezaee K; Majidpoor J
Biomed Pharmacother; 2023 Jul; 163():114824. PubMed ID: 37141735
[TBL] [Abstract][Full Text] [Related]
20. Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment.
Wu S; Huang H; Sun R; Gao DS; Ye F; Huang J; Li E; Ni A; Lu KG; Chen K; Jiang J; Morel PA; Zhong Z; Lu B
Cancer Res Commun; 2023 Aug; 3(8):1460-1472. PubMed ID: 37546701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
